View the latest news and SEC filings
Scroll to
Approximately $36 million and $42 million net product sales of Ohtuvayre for the fourth quarter and full year 2024, respectively More than 3,500 unique prescribers and over 16,000 prescriptions filled in 2024 across a broad COPD population Approximately 45% of Tier 1 HCPs prescribed Ohtuvayre
LONDON and RALEIGH, N.C., Nov. 19, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the following conferences in December 2024: Piper Sandler 36 th Annual Healthcare Conference Date:
LONDON and RALEIGH, N.C., Nov. 05, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 6:30 a.m. ET / 11:30 a.m.
Ohtuvayre™ (ensifentrine) launch recorded Q3 net sales of $5.6 million and October net sales exceeded Q3 Through October more than 2,200 unique prescribers and more than 5,000 prescriptions filled across a broad COPD population Pipeline expansion continues: Phase 2 programs enrolling Conference
| Date | Form | Filing Group | ||
|---|---|---|---|---|
|
March 3, 2021 |
Statement of changes in beneficial ownership of securities |
4 |
3,4,5 |
|
|
March 3, 2021 |
Initial filing by director officer or owner of more than ten percent. |
3 |
3,4,5 |
|
|
March 2, 2021 |
Report of unscheduled material events or corporate event |
8-K |
Current Reports |
|
|
February 25, 2021 |
Annual report which provides a comprehensive overview of the company for the past year |
10-K |
Annual Filings |
|
|
February 25, 2021 |
Report of unscheduled material events or corporate event |
8-K |
Current Reports |
|
|
February 16, 2021 |
A statement of beneficial ownership of common stock by certain persons |
SC 13G |
Other |
|
|
February 5, 2021 |
An amendment to the SC 13G filing |
SC 13G/A |
Other |
|
|
February 3, 2021 |
Statement of changes in beneficial ownership of securities |
4 |
3,4,5 |
|
|
February 3, 2021 |
Statement of changes in beneficial ownership of securities |
4 |
3,4,5 |
Verona Pharma (Nasdaq:VRNA) is focused on delivering our strategy and creating value for shareholders.
